The Association of Aldosterone With Obesity-Related Hypertension and the Metabolic Syndrome

Seminars in Nephrology

Volumn 27, Issue 5, 2007, Pages 529-537

  Vogt, Bruno ^a   Bochud, Murielle ^b   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

12,13 epoxy 9 keto 10 trans octadecenoic acid (EKODE); aldosterone; angiotensin; fatty acid; hypertension; Metabolic syndrome; sodium

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANGIOTENSINOGEN; DROSPIRENONE; EPLERENONE; ESTROGEN DERIVATIVE; FATTY ACID; LIPID; RENIN; ROSIGLITAZONE; SPIRONOLACTONE;

ADIPOSE TISSUE; ALDOSTERONE BLOOD LEVEL; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; ESTERIFICATION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYPERALDOSTERONISM; HYPERTENSION; HYPERTENSIVE CRISIS; LIPID BLOOD LEVEL; LIPID METABOLISM; METABOLIC SYNDROME X; NONHUMAN; OBESITY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SLEEP APNEA SYNDROME;

ADIPOSE TISSUE; ALDOSTERONE; ANIMALS; BLOOD PRESSURE; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; OBESITY; PROGNOSIS; RISK FACTORS;

EID: 34548493959     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.07.009     Document Type: Article

References (86)

1. Antic V., Dulloo A., and Montani J.P. Multiple mechanisms involved in obesity-induced hypertension. Heart Lung Circ 12 (2003) 84-93
2. Eckel R.H., Grundy S.M., and Zimmet P.Z. The metabolic syndrome. Lancet 365 (2005) 1415-1428
3. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112 (2005) 2735-2752
4. Alberti K.G., Zimmet P., and Shaw J. The metabolic syndrome-a new worldwide definition. Lancet 366 (2005) 1059-1062
5. Must A., Spadano J., Coakley E.H., et al. The disease burden associated with overweight and obesity. JAMA 282 (1999) 1523-1529
6. Jones D.W., Kim J.S., Andrew M.E., et al. Body mass index and blood pressure in Korean men and women: the Korean National Blood Pressure Survey. J Hypertens 12 (1994) 1433-1437
7. Rocchini A.P., Moorehead C.P., DeRemer S., et al. Pathogenesis of weight-related changes in blood pressure in dogs. Hypertension 13 (1989) 922-928
8. Goodfriend T.L., Egan B.M., and Kelley D.E. Aldosterone in obesity. Endocr Res 24 (1998) 789-796
9. Engeli S., Bohnke J., Gorzelniak K., et al. Weight loss and the renin-angiotensin-aldosterone system. Hypertension 45 (2005) 356-362
10. Tuck M.L., Sowers J., Dornfeld L., et al. The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304 (1981) 930-933
11. Neter J.E., Stam B.E., Kok F.J., et al. Influence of weight reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 42 (2003) 878-884
12. Garrison R.J., Kannel W.B., Stokes III J., et al. Incidence and precursors of hypertension in young adults: the Framingham Offspring Study. Prev Med 16 (1987) 235-251
13. McTigue K., Larson J.C., Valoski A., et al. Mortality and cardiac and vascular outcomes in extremely obese women. JAMA 296 (2006) 79-86
14. Mancia G., Bousquet P., Elghozi J.L., et al. The sympathetic nervous system and the metabolic syndrome. J Hypertens 25 (2007) 909-920
15. Reaven G.M., Lithell H., and Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 334 (1996) 374-381
16. Peppard P.E., Young T., Palta M., et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342 (2000) 1378-1384
17. Young T., Peppard P., Palta M., et al. Population-based study of sleep-disordered breathing as a risk factor for hypertension. Arch Intern Med 157 (1997) 1746-1752
18. Hla K.M., Young T.B., Bidwell T., et al. Sleep apnea and hypertension. A population-based study. Ann Intern Med 120 (1994) 382-388
19. Hall J.E. The kidney, hypertension, and obesity. Hypertension 41 (2003) 625-633
20. Goodfriend T.L., and Calhoun D.A. Resistant hypertension, obesity, sleep apnea, and aldosterone: theory and therapy. Hypertension 43 (2004) 518-524
21. Rocchini A.P. Obesity hypertension. Am J Hypertens 15 (2002) 50S-52S
22. Sarafidis P.A., and Bakris G.L. Non-esterified fatty acids and blood pressure elevation: a mechanism for hypertension in subjects with obesity/insulin resistance?. J Hum Hypertens 21 (2007) 12-19
23. Davy K.P., and Hall J.E. Obesity and hypertension: two epidemics or one?. Am J Physiol 286 (2004) R803-R813
24. Rahmouni K., Correia M.L., Haynes W.G., et al. Obesity-associated hypertension: new insights into mechanisms. Hypertension 45 (2005) 9-14
25. Burnier M. Spotlight on renin. The renin-angiotensin-aldosterone system and metabolic syndrome. J Renin Angiotensin Aldosterone Syst 7 (2006) 184
26. Egan B.M., Stepniakowski K., and Goodfriend T.L. Renin and aldosterone are higher and the hyperinsulinemic effect of salt restriction greater in subjects with risk factors clustering. Am J Hypertens 7 (1994) 886-893
27. Bochud M., Nussberger J., Bovet P., et al. Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48 (2006) 239-245
28. Engeli S., Negrel R., and Sharma A.M. Physiology and pathophysiology of the adipose tissue renin-angiotensin system. Hypertension 35 (2000) 1270-1277
29. Massiera F., Seydoux J., Geloen A., et al. Angiotensinogen-deficient mice exhibit impairment of diet-induced weight gain with alteration in adipose tissue development and increased locomotor activity. Endocrinology 142 (2001) 5220-5225
30. Gorzelniak K., Engeli S., Janke J., et al. Hormonal regulation of the human adipose-tissue renin-angiotensin system: relationship to obesity and hypertension. J Hypertens 20 (2002) 965-973
31. Janke J., Engeli S., Gorzelniak K., et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 38 (2006) 28-33
32. Harte A., McTernan P., Chetty R., et al. Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 111 (2005) 1954-1961
33. Harte A.L., McTernan P.G., McTernan C.L., et al. Insulin increases angiotensinogen expression in human abdominal subcutaneous adipocytes. Diabetes Obes Metab 5 (2003) 462-467
34. Janke J., Schupp M., Engeli S., et al. Angiotensin type 1 receptor antagonists induce human in-vitro adipogenesis through peroxisome proliferator-activated receptor-gamma activation. J Hypertens 24 (2006) 1809-1816
35. Tomlinson J.W., and Stewart P.M. Mechanisms of disease: selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome. Nat Clin Pract Endocrinol Metab 1 (2005) 92-99
36. Mariniello B., Ronconi V., Rilli S., et al. Adipose tissue 11beta-hydroxysteroid dehydrogenase type 1 expression in obesity and Cushing's syndrome. Eur J Endocrinol 155 (2006) 435-441
37. Jensen M.D., Haymond M.W., Rizza R.A., et al. Influence of body fat distribution on free fatty acid metabolism in obesity. J Clin Invest 83 (1989) 1168-1173
38. Martin M.L., and Jensen M.D. Effects of body fat distribution on regional lipolysis in obesity. J Clin Invest 88 (1991) 609-613
39. Grekin R.J., Vollmer A.P., and Sider R.S. Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 26 (1995) 193-198
40. Stojiljkovic M.P., Zhang D., Lopes H.F., et al. Hemodynamic effects of lipids in humans. Am J Physiol 280 (2001) R1674-R1679
41. Lopes H.F., Stojiljkovic M.P., Zhang D., et al. Moderate sodium restriction enhances the pressor response to hyperlipidemia in obese, hypertensive patients. J Clin Hypertens 4 (2002) 173-180
42. Goodfriend T.L., Ball D.L., and Gardner H.W. An oxidized derivative of linoleic acid affects aldosterone secretion by adrenal cells in vitro. Prostaglandins Leukot Essent Fatty Acids 67 (2002) 163-167
43. Goodfriend T.L., Ball D.L., Egan B.M., et al. Epoxy-keto derivative of linoleic acid stimulates aldosterone secretion. Hypertension 43 (2004) 358-363
44. Ehrhart-Bornstein M., Lamounier-Zepter V., Schraven A., et al. Human adipocytes secrete mineralocorticoid-releasing factors. Proc Natl Acad Sci U S A 100 (2003) 14211-14216
45. Nagase M., Yoshida S., Shibata S., et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol 17 (2006) 3438-3446
46. Epstein M. Resistant hypertension: prevalence and evolving concepts. J Clin Hypertens 9 (2007) 2-6
47. Wolk R., and Somers V.K. Obesity-related cardiovascular disease: implications of obstructive sleep apnea. Diabetes Obes Metab 8 (2006) 250-260
48. Rocchini A.P., Katch V.L., Grekin R., et al. Role for aldosterone in blood pressure regulation of obese adolescents. Am J Cardiol 57 (1986) 613-618
49. Gordon R.D., Stowasser M., Tunny T.J., et al. High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 21 (1994) 315-318
50. Lim P.O., Rodgers P., Cardale K., et al. Potentially high prevalence of primary aldosteronism in a primary-care population. Lancet 353 (1999) 40
51. Lim P.O., Dow E., Brennan G., et al. High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 14 (2000) 311-315
52. Fardella C.E., Mosso L., Gomez-Sanchez C., et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 85 (2000) 1863-1867
53. Mosso L., Carvajal C., Gonzalez A., et al. Primary aldosteronism and hypertensive disease. Hypertension 42 (2003) 161-165
54. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40 (2002) 892-896
55. Gallay B.J., Ahmad S., Xu L., et al. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 37 (2001) 699-705
56. Fallo F., Veglio F., Bertello C., et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J Clin Endocrinol Metab 91 (2006) 454-459
57. Pratt-Ubunama M.N., Nishizaka M.K., Boedefeld R.L., et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131 (2007) 453-459
58. Logan A.G., Perlikowski S.M., Mente A., et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 19 (2001) 2271-2277
59. Calhoun D.A., Nishizaka M.K., Zaman M.A., et al. Aldosterone excretion among subjects with resistant hypertension and symptoms of sleep apnea. Chest 125 (2004) 112-117
60. Sartori M., Calo L.A., Mascagna V., et al. Aldosterone and refractory hypertension: a prospective cohort study. Am J Hypertens 19 (2006) 373-380
61. Nishizaka M.K., Zaman M.A., and Calhoun D.A. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 16 (2003) 925-930
62. Ouzan J., Perault C., Lincoff A.M., et al. The role of spironolactone in the treatment of patients with refractory hypertension. Am J Hypertens 15 (2002) 333-339
63. Yamashita R., Kikuchi T., Mori Y., et al. Aldosterone stimulates gene expression of hepatic gluconeogenic enzymes through the glucocorticoid receptor in a manner independent of the protein kinase B cascade. Endocr J 51 (2004) 243-251
64. Campion J., Maestro B., Molero S., et al. Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem Funct 20 (2002) 237-245
65. Giacchetti G., Ronconi V., Turchi F., et al. Aldosterone as a key mediator of the cardiometabolic syndrome in primary aldosteronism: an observational study. J Hypertens 25 (2007) 177-186
66. Widimsky Jr. J., Sindelka G., Haas T., et al. Impaired insulin action in primary hyperaldosteronism. Physiol Res 49 (2000) 241-244
67. Strauch B., Widimsky J., Sindelka G., et al. Does the treatment of primary hyperaldosteronism influence glucose tolerance?. Physiol Res 52 (2003) 503-506
68. Widimsky Jr. J., Strauch B., Sindelka G., et al. Can primary hyperaldosteronism be considered as a specific form of diabetes mellitus?. Physiol Res 50 (2001) 603-607
69. Andronico G., Cottone S., Mangano M.T., et al. Insulin, renin-aldosterone system and blood pressure in obese people. Int J Obes Relat Metab Disord 25 (2001) 239-242
70. Goodfriend T.L., Egan B., Stepniakowski K., et al. Relationships among plasma aldosterone, high-density lipoprotein cholesterol, and insulin in humans. Hypertension 25 (1995) 30-36
71. Kidambi S., Kotchen J.M., Grim C.E., et al. Association of adrenal steroids with hypertension and the metabolic syndrome in blacks. Hypertension 49 (2007) 704-711
72. Sindelka G., Widimsky J., Haas T., et al. Insulin action in primary hyperaldosteronism before and after surgical or pharmacological treatment. Exp Clin Endocrinol Diabetes 108 (2000) 21-25
73. Liu G., Grifman M., Keily B., et al. Mineralocorticoid receptor is involved in the regulation of genes responsible for hepatic glucose production. Biochem Biophys Res Commun 342 (2006) 1291-1296
74. Goodfriend T.L., Egan B.M., and Kelley D.E. Plasma aldosterone, plasma lipoproteins, obesity and insulin resistance in humans. Prostaglandins Leukot Essent Fatty Acids 60 (1999) 401-405
75. Lind L., Lithell H., Wide L., et al. Metabolic cardiovascular risk factors and the renin-aldosterone system in essential hypertension. J Hum Hypertens 6 (1992) 27-29
76. Oelkers W., Foidart J.M., Dombrovicz N., et al. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 (1995) 1816-1821
77. White W.B., Hanes V., Chauhan V., et al. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 48 (2006) 246-253
78. Tanko L.B., and Christiansen C. Effects of 17beta-oestradiol plus different doses of drospirenone on adipose tissue, adiponectin and atherogenic metabolites in postmenopausal women. J Intern Med 258 (2005) 544-553
79. Gaudio G., Guasti L., Schizzarotto A., et al. Changes in plasma lipids during renin-angiotensin system blockade by combination therapy (enalapril plus valsartan) in patients with diabetes and hypertension. J Cardiovasc Pharmacol 45 (2005) 362-366
80. Takai S., Jin D., Muramatsu M., et al. Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46 (2005) 1135-1139
81. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341 (1999) 709-717
82. Pitt B., White H., Nicolau J., et al. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46 (2005) 425-431
83. Egan B.M., Papademetriou V., Wofford M., et al. Metabolic syndrome and insulin resistance in the TROPHY sub-study: contrasting views in patients with high-normal blood pressure. Am J Hypertens 18 (2005) 3-12
84. Russo P., Lauria F., Loguercio M., et al. -344C/T Variant in the promoter of the aldosterone synthase gene (CYP11B2) is associated with metabolic syndrome in men. Am J Hypertens 20 (2007) 218-222
85. de Paula R.B., da Silva A.A., and Hall J.E. Aldosterone antagonism attenuates obesity-induced hypertension and glomerular hyperfiltration. Hypertension 43 (2004) 41-47
86. Engeli S., Schling P., Gorzelniak K., et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome?. Int J Biochem Cell Biol 35 (2003) 807-825